Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Influenza and COVID-19 Vaccine in Healthy Individuals
NCT06683352Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza and coronavirus disease 2019 (COVID-19) (15 arms), sponsored by BioNTech SE. Primary endpoints: Percentage of Participants With Any Local Reactions at 7 days, Percentage of Participants With Any Systemic Events at 7 days and 2 more. Started Nov 2024; status: completed.
02
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06683352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683352.